Lamivudine is not effective in primary Sjögren's syndrome.
BACKGROUND
Retroviral infection has been implicated in the pathogenesis of primary Sjögren's syndrome.


OBJECTIVE
To examine the efficacy of the reverse transcriptase inhibitor lamivudine in patients with this syndrome.


METHODS
16 patients with primary Sjögren's syndrome were randomised to receive either lamivudine 150 mg twice daily or placebo for three months. Measures of lacrimal and salivary function, including minor salivary gland biopsies, were obtained before and after treatment.


RESULTS
Treatment with lamivudine did not result in significant improvement in the primary outcome measure of unstimulated whole salivary flow or other secondary measures, including minor salivary gland biopsy focus scores.


CONCLUSIONS
Lamivudine is not effective in patients with primary Sjögren's syndrome, suggesting either that a retroviral aetiology is not present or that it may be important only in early disease.
Gescuk
B
B
Clinical Trials Center, Division of Rheumatology, University of California, San Francisco, 533 Parnassus Avenue Box 0633 Room U383, San Francisco, CA 94143-0633, USA.
Wu
A J
AJ
Whitcher
J P
JP
Daniels
T E
TE
Lund
S
S
Fye
K
K
Davis
J C
JC
D000328:Adult; D001706:Biopsy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D012470:Salivary Glands, Minor / Q000473:pathology; D012472:Salivation / Q000187:drug effects; D012720:Severity of Illness Index; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology; D013666:Tears / Q000378:metabolism; D017211:Treatment Failure
D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine